Adjuvant endocrine therapy (AET) roughly halves the risk of recurrence among the two-thirds of premenopausal breast cancer patients whose tumors over-express the estrogen receptor (i.e., estrogen receptor positive [ER+]) [1, 2]. Here, ESR1 is linked to breast cancer.